E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
advanced hepatocellular carcinoma |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This is a combined phase 1 and phase 2 study with the following primary objectives:
Phase 1 • safety and tolerability of daily RAD001 in combination with daily sorafenib in adult patients with advanced hepatocellular carcinoma (HCC) who have taken no prior systemic therapy for HC and to determine the maximum tolerated dose (MTD) of the combination of RAD001 plus sorafenib to bring forward into phase 2
Phase 2 • To estimate the hazard ratio of the treatment effect as a measure of anti-tumor activity in terms of Time to Progression (TTP) of the combination of RAD001 plus sorafenib, at the MTD level, as compared to sorafenib alone |
|
E.2.2 | Secondary objectives of the trial |
Phase 1
• efficacy of RAD001 + sorafenib at the explored dose-levels in terms of best overall response as defined by RECIST • safety and tolerability of of RAD001 + sorafenib as measured by rate and severity of AEs • To determine the steady state exposure of RAD001 at pre-dose and 1 hour and 2 hours post-dose at the explored combination dose-levels using concentrations at pre-dose (Cmin) and at 1 hour (C1h) and 2 hours (C2h) post-dose
Phase 2
• clinical efficacy in terms of the following endpoints according to RECIST: • Best overall response • PFS • To compare overall survival of RAD001 + sorafenib with sorafenib alone • safety and tolerability of of RAD001 + sorafenib as measured by rate and severity of AEs To determine the steady state exposure of RAD001 at pre-dose and 1 hour and 2 hours post-dose at the explored combination dose-levels using concentrations at pre-dose (Cmin) and at 1 hour (C1h) and 2 hours (C2h) post-dose |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female patients = 18 years old with ability to take oral drugs 2. Diagnosis of advanced HCC according to the AASLD Guidelines (Bruix and Sherman 2005) 3. HCC stage B or C according to the Barcelona Clinic Liver Cancer (BCLC) (Llovet, et al 2008b) 4. No previous systemic therapy for HCC, (tamoxifen is allowed as previous systemic therapy) 5. Measurable disease according to RECIST, i.e. at least one measurable lesion. This lesion should not have been previously treated with local therapy. A treated lesion may be used where these lesions are the only lesions available for evaluation and have shown definite progression since their last local radiation treatment. Local therapy must have been completed at least four weeks prior to baseline evaluation 6. Patients with ECOG performance status of 0 or 1 (see Section 7.5.4) 7. Cirrhotic status of current Child-Pugh class A only (5-6 points) with no encephalopathy and no ascites (ascites controlled by diuretics is excluded). Child-Pugh status should be calculated based on clinical findings and laboratory results during the screening period. 8. For patients with background chronic hepatitis B virus (HBV), they must be treated with lamivudine QD 100 mg, (or alternative treatment if resistant to lamivudine), as prophylaxis at least 2 weeks prior to receiving study drug, Visit 2. 9. The following laboratory parameters at Visit 2: • Absolute Neutrophil Count (ANC) = 1.5 x 109/L • Platelets = 70000 x 106/L • Hemoglobin (Hgb) = 9 g/dL • Serum aspartate aminotransferase (AST) and alanine amino-transferase (ALT) = 5 x ULN • Serum creatinine = 1.5 x ULN 10. Ability to understand and willingness to sign a written informed consent and to be able to follow the visit schedule
|
|
E.4 | Principal exclusion criteria |
1. Patients currently receiving any anti cancer therapy or who have received any local anti cancer therapy = 4 weeks prior to baseline CT/MRI scan, Visit 2 2. Active bleeding during the last 30 days prior to Visit 1 including variceal bleeding (Esophageal varices should be treated according to standard practice e.g. ligation/banding and procedure completed 30 days prior to Visit 1.) 3. Patients with a known hypersensitivity to RAD001 (everolimus) or known hypersensitivity to sorafenib or contradictions to sorafenib based on the local sorafenib label 4. Known previous/current malignancy requiring treatment within = 3 years except for cervical carcinoma in situ, basal cell carcinoma, and superficial bladder carcinoma 5. Known history of human immunodeficiency virus (HIV) seropositivity, (HIV testing is not mandatory) 6. Any severe and/or uncontrolled medical conditions including: • Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction = 6 months prior to Visit 1, serious uncontrolled cardiac arrhythmia, uncontrolled hypertension • Previous TIA, CVA, symptomatic PVD within last 6 months of Visit 1 • Patients with active alcohol intake • Uncontrolled diabetes as defined by HbA1c >8% • Greater or equal grade 3 hypercholesterolemia/hypertriglyceridemia or = grade 2 hypercholesterolemia/hypertriglyceridemia with history of coronary artery disease (despite lipid-lowering treatment if given) • Acute and chronic, active infectious disorders and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy, in the opinion of the investigator, except chronic HBV or hepatitis C virus (HCV). • Impairment of gastrointestinal function or who have gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome) • Significant deterioration of lung function, defined as any of the following: 30% decrease in predicted lung volumes, and/or 30% decrease in DLCO, and/or = 88% O2 saturation at rest on room air 7. Patients receiving chronic treatment with corticosteroids (except for intermittent topical or local injection or aldosterone) or another immunosuppressive agent 8. Patients treated with drugs known to be strong inhibitors or inducers of isoenzyme CYP3A (see Table 6-5) unless the drugs are medically necessary and no substitutes are available. If there are no acceptable substitutes, special precautions should be taken in these patients (see Section 6.5.8.8). 9. Patients who have undergone major surgery = 2 weeks prior to starting study drug or who have not recovered from surgery 10. Female patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. Adequate contraceptives must be used throughout the trial and for 3 months after last study drug administration in both sexes. Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to administration of RAD001 and/or sorafenib. 11. Patients who have received an investigative drug or therapy within the last 30 days prior to Visit 1 12. Patients unwilling or unable to comply with the protocol, in the opinion of the investigator |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Phase 1 • Probability of DLT (Dose Limiting Toxicity) occurring during the first 28 days of combined treatment of RAD001 with sorafenib
Phase 2 • Time to Progression
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
combined phase 1 / phase 2 trial |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
phase 1: open, non-randomized; phase 2: double-blind, randomized |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
end of trial will be LPLV (last visit of the last patient of this trial) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |